Small Cap most volatile: Net 1 UEPS Technologies (NASDAQ:UEPS), Avanir Pharmaceuticals (NASDAQ:AVNR), Global Eagle Acquisition (NASDAQ:ENT), TherapeuticsMD (NYSEMKT:TXMD)

On April 17, 2014, Net1 UEPS Technologies Inc. (NASDAQ:UEPS) issued a press release which announced that the South African Constitutional Court has ruled on the appropriate remedy following its declaration on November 29, 2013, that the tender process followed by the South African Social Security Agency in awarding a contract to Net1’s wholly owned subsidiary Cash Paymaster Services Proprietary Limited was constitutionally invalid. Net 1 UEPS Technologies Inc. (NASDAQ:UEPS) shares after opening at $7.04 moved to $9.18 on last trade day and at the end of the day closed at $8.98. Company price to sales ratio in past twelve months was calculated as 0.84 and price to cash ratio as 18.36. Net 1 UEPS Technologies Inc. (NASDAQ:UEPS) showed a negative weekly performance of -7.37%.

Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) on 26 march announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) of AVP-825, its innovative Breath Powered™ investigational drug-device combination product for the acute treatment of migraine. Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) shares advanced 1.17% in last trading session and ended the day on $3.46. AVNR return on equity ratio is recorded as -362.80% and its return on assets is -99.70%. Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) yearly performance is 16.89%.

Global Eagle Acquisition Corp (NASDAQ:ENT) very impressive revenue growth greatly exceeded the industry average of 16.5%. Since the same quarter one year prior, revenues leaped by 286.0%. Growth in the company’s revenue appears to have helped boost the earnings per share. Global Eagle Acquisition Corp (NASDAQ:ENT) shares moved up 6.72% in last trading session and was closed at $13.18, while trading in range of $12.27 – $13.32. Global Eagle Acquisition Corp (NASDAQ:ENT) year to date (YTD) performance is -11.37%.

Stock analysts at Noble Financial increased their price target on shares of TherapeuticsMD (NASDAQ:TXMD) from $9.00 to $13.00 in a report issued on Thursday, American Banking News reports. The firm currently has a “buy” rating on the stock. Noble Financial’s price target would suggest a potential upside of 177.19% from the company’s current price. TherapeuticsMD Inc. (NYSEMKT:TXMD) weekly performance is 4.26%. On last trading day company shares ended up $4.90. TherapeuticsMD Inc. (NYSEMKT:TXMD) distance from 50-day simple moving average (SMA50) is -22.99%. Analysts mean target price for the company is $8.75.